Drugs / PXL770
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05441904 | Mar 2021 | metabolic dysfunction-associated steatohepatitis | Poxel SA | Completed | No outcome recorded |
| Phase 1 | NCT03950882 | Aug 2019 → Mar 2020 | NAFLD1 | Poxel SA | Completed | No outcome recorded |
| Phase 1 | NCT03886103 | Feb → Mar 2019 | — | Poxel SA | Completed | No outcome recorded |
| Phase 1 | NCT03395470 | Aug 2017 → Mar 2018 | metabolic disease | Poxel SA | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05146284 | Sep 2023 → Sep 2024 | adrenomyeloneuropathy | Poxel SA | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03763877 | Mar 2019 → Aug 2020 | NAFLD1 | Poxel SA | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PXL770 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03950882 ↗ |
| Action | Activate | “PXL770 is a direct activator of 5' adenosine monophosphate-activated protein kinase (AMPK)” NCT03395470 ↗ |
| Route | Oral | “to receive oral PXL770 250 mg once daily, 250 mg twice daily, or 500 mg once daily, or matched placebo” PMID 34560015 ↗ Sep 2021 |